For Better or for Worse: COVID-19 Vaccination during or Early after (Immuno-) Chemotherapy or Hematopoietic Progenitor Cell Transplantation

Background: Patients with hematologic conditions have a high mortality rate when infected with SARS-CoV-2 (Williamson, Nature 2020). Protection of this group from severe COVID-19 is therefore important. However, according to available vaccination guidelines, one should consider to postpone vaccinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Haggenburg, Sabine, Lissenberg-Witte, Birgit I., Van Binnendijk, Robert S., Den Hartog, Gerco, Michel, Bhoekhan S., Haverkate, Nienke J.E., De Rooij, Dennis M., Broers, Annoek E.C., Mutsaers, Pim G.N.J., Van Meerten, Tom, van Doesum, Jaap, Kater, Arnon P., Zweegman, Sonja, Van Gils, Marit J., Goorhuis, Bram, Rutten, Caroline E., Hazenberg, Mette D., Nijhof, Inger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
901.Health Services Research-Non-Malignant Conditions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701639/
http://dx.doi.org/10.1182/blood-2021-150379

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701639/
http://dx.doi.org/10.1182/blood-2021-150379

Ejemplares similares